Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
about
Erythropoietin or darbepoetin for patients with cancer'More than just money' -- widening the understanding of the costs involved in cancer care.Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.Erythropoietin after a century of research: younger than ever.The development of erythropoietic agents in oncology.Epoetin alfa: basic biology and clinical utility in cancer patients.Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients.Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.The skin as a biofactory for systemic secretion of erythropoietin: potential of genetically modified keratinocytes and fibroblasts.Comparative costs of treatment with epoetin alfa and darbepoetin alfa for anemia in the oncology and nephrology settings.Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy.A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.Erythropoietin: can we afford to use it? Can we afford not to?
P2860
Q24202335-133B5F1D-0910-4736-A118-C4993CEDFE3AQ34184814-C71739A4-E41D-44A5-B594-2D5EC3CF3F34Q34337012-8E627F76-B9C3-4FD8-8296-76B6928222C1Q34606348-B1A90643-0D1D-4084-BF53-79B2B12628CBQ36219651-0686AF52-C9BB-4389-975B-FE61E1EA91DAQ36334861-228A87FC-A49C-4FBB-BF14-739BF8ACDF13Q37058440-320C0597-25C8-4268-9D6C-0EC3C638F5B7Q37766575-1ACFF5E4-CFCD-4AAC-88DB-45A7DF2333CCQ42991737-5B13D38D-C1CE-493B-8651-93337107BA69Q43034061-53DFA620-4602-4E3D-A0B3-8017857933F0Q45875820-D8AFBD14-FBEE-4DF6-8B07-A7FDD851509AQ46796057-CD2F9DEB-0458-4441-85AF-5E4EEA5ABC14Q50485217-52164963-BF1D-46C9-AF0E-457624FE7CAAQ50683481-EA6947D5-1EDD-440C-A3A4-5C7C1929D0B9Q50732390-367CBB2D-CE62-4770-80E9-CE3E105651DB
P2860
Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@ast
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@en
type
label
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@ast
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@en
prefLabel
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@ast
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@en
P2093
P2860
P356
P1476
Cost-effectiveness of recombin ...... chemotherapy-induced anaemia.
@en
P2093
Liberato NL
Marchetti M
P2860
P2888
P304
P356
10.1038/BJC.1998.579
P407
P577
1998-09-01T00:00:00Z